Last reviewed · How we verify
NCT06359327
Effect of Consumption of Pep19 on Quality of Life
NA trial testing Placebo in Quality of Life in 24 participants. Completed in 15 August 2024.
28 July 2024
Quick facts
| Lead sponsor | Proteimax Biotechnology Israel LTD |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 24 |
| Start date | 28 May 2024 |
| Primary completion | 28 July 2024 |
| Estimated completion | 15 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Placebo
- Pep19 2 mg
- Pep19 5 mg
Conditions studied
- Quality of Life — all drugs for Quality of Life →
- Obesity — all drugs for Obesity →
- Sleep Quality — all drugs for Sleep Quality →
Sponsor
Proteimax Biotechnology Israel LTD
Who can join
Adults 40 to 60, any sex, with Quality of Life or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pep19 is a naturally occurring peptide (protein) that triggers loss of body fat. It has been certified Generally Recognized as Safe (GRAS) at up to 3.8 grams per day and may be included in various foods. Pep19 has no effect on the brain, heart, pancreas or skeletal muscle. It is highly purified, not allergenic or mutagenic, and free of microbes, metals and other contaminants. Preliminary, open-label, uncontrolled studies have shown that Pep19 is well tolerated in rodents, dogs, and humans. This placebo-controlled study will evaluate the effects of two doses of Pep19™ -- 2 mg and 5 mg - on quality of life and sleep quality in obese subjects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults-Results From an Early-Stage Clinical Trial.
Heimann AS, Singh P, Ferro ES, Greenway F, et al · · 2025 · PMID 40450548 · DOI 10.1002/dmrr.70056
Verify or expand the search:
- PubMed search for NCT06359327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Quality of Life
Currently open trials in the same condition.
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT07416448 — Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting
- NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07280416 — Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06359327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Proteimax Biotechnology Israel LTD
- Last refreshed: 6 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06359327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing